Souto Eliana B, Doktorovová Slavomira
Department of Pharmaceutical Technology, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal.
Methods Enzymol. 2009;464:105-29. doi: 10.1016/S0076-6879(09)64006-4.
Solid lipid nanoparticles (SLNs) have emerged as important tools to modify the release profile for a large number of drugs including protein and peptide molecules. SLNs are produced from biocompatible and biodegradable lipid materials, making them a promising therapeutic strategy for drug targeting and delivery, and surmounting the inherent limitations of regulation acceptance. Due to their versatility in loading both lipophilic and hydrophilic molecules in the solid lipid matrix, SLNs depict the ability to prolong, extend or sustain the release profile of the loaded molecules, therefore reducing the repeated administration, and increasing the therapeutic value of a certain treatment. Additional advantages include reduction of drug toxicity and increase of drug bioavailability. To develop SLN formulations for drug targeting and delivery, a basic pharmacokinetic understanding of drug distribution is of major relevance, as well as the biopharmaceutical aspects of the administration route. This chapter provides a fundamental understanding of the pharmacokinetic properties of SLNs, which influence both biopharmaceutical and clinical profiles of the loaded molecules.
固体脂质纳米粒(SLNs)已成为改变包括蛋白质和肽分子在内的大量药物释放曲线的重要工具。SLNs由生物相容性和可生物降解的脂质材料制成,使其成为药物靶向和递送的一种有前景的治疗策略,并克服了监管接受方面的固有局限性。由于其在固体脂质基质中负载亲脂性和亲水性分子的多功能性,SLNs具有延长、扩展或维持负载分子释放曲线的能力,因此减少了重复给药,并提高了特定治疗的治疗价值。其他优点包括降低药物毒性和提高药物生物利用度。为了开发用于药物靶向和递送的SLN制剂,对药物分布的基本药代动力学理解以及给药途径的生物药剂学方面具有重要意义。本章提供了对SLNs药代动力学特性的基本理解,这些特性会影响负载分子的生物药剂学和临床特征。